biote (NASDAQ:BTMD – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for biote and Mangoceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| biote | 1 | 1 | 1 | 1 | 2.50 |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
biote presently has a consensus target price of $2.50, suggesting a potential upside of 55.28%. Given biote’s stronger consensus rating and higher probable upside, equities analysts clearly believe biote is more favorable than Mangoceuticals.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| biote | 3.19% | -22.33% | 12.10% |
| Mangoceuticals | -4,794.60% | -96.39% | -89.60% |
Institutional and Insider Ownership
21.7% of biote shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 32.4% of biote shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares biote and Mangoceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| biote | $192.22 million | 0.30 | $27.05 million | $0.11 | 14.64 |
| Mangoceuticals | $315,227.00 | 28.87 | -$20.64 million | ($1.01) | -0.42 |
biote has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
biote has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
Summary
biote beats Mangoceuticals on 12 of the 15 factors compared between the two stocks.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.
